Syndax Pharmaceuticals, Inc. (SNDX) Financial Statements
Syndax Pharmaceuticals, Inc. (SNDX) reported trailing twelve-month revenue of $252.3M (up 222.7% year on year) and net income of -$220.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$220.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SNDXSyndax Pharmaceuticals, Inc.Follow SNDX — free
—
Price chart with a free account
- Market cap
- 1.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2 | 2.1 | 1.5 | 1.5 | 1.5 | 139.7 | 23.7 | 172.4 | 252.3 | |
| Gross profit | — | — | — | — | — | — | 22.9 | 165.4 | — | |
| Research & development | 31.7 | 48.2 | 60.1 | 43.0 | 50.4 | 88.2 | 241.6 | 258.8 | 261.8 | |
| Operating income | -43.8 | -62.0 | -75.9 | -57.5 | -71.4 | 26.2 | -339.7 | -273.1 | -194.2 | |
| Pre-tax income | -44.5 | -60.8 | -74.0 | -56.0 | -73.2 | 24.9 | -318.8 | -285.0 | -220.3 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | 0.4 | 0.4 | |
| Net income | -44.5 | -60.8 | -74.0 | -56.0 | -73.2 | 24.9 | -318.8 | -285.4 | -220.8 | |
| Diluted EPS ($) | -3.22 | -2.90 | -2.92 | -1.84 | -1.87 | 0.46 | -3.72 | -3.29 | -2.51 | |
| Diluted shares (mn) | — | — | — | — | — | 53.6 | 85.6 | 86.6 | — |
USD millions · SEC XBRL
Syndax Pharmaceuticals, Inc. — questions
- What is Syndax Pharmaceuticals, Inc.'s revenue?
- $252.3M over the twelve months to 2026-06-30, up 222.7% year on year, from its 10-Q and 10-K filings.
- What is Syndax Pharmaceuticals, Inc.'s net income?
- -$220.8M over the twelve months to 2026-06-30.
- What is Syndax Pharmaceuticals, Inc.'s free cash flow?
- -$220.9M over the twelve months to 2026-06-30.
- What are Syndax Pharmaceuticals, Inc.'s diluted earnings per share?
- $-2.51 over the twelve months to 2026-06-30.
Every figure on this page comes from Syndax Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.